X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 4c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q4 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.43 million versus the consensus estimate of $990.71 thousand.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Brookfield offers A$4.75/sh for Reliance Worldwide - Bloomberg